فروشگاه

Name: Islet 1 Monoclonal Antibody clone EP283

Description and aplications: Islet-1, Insulin gene enhancer protein ISL-1, is a protein that in humans is encoded by the ISL1 gene. This gene encodes a transcription factor containing two N-terminal LIM domains and one C-terminal homeo domain. The encoded protein plays an important role in the embryogenesis of pancreatic islets of Langerhans. ISL1 has been shown to interact with Estrogen Receptor alpha. Islet-1 produces a strong nuclear staining in the islets of normal pancreas and tumor cells of the pancreatic neuroendocrine tumors. Islet-1 has been found to be a reliable marker of pancreatic endocrine tumors and metastasis. It shows a comparable sensitivity and specificity as CDX2 as a marker of ileal and appendiceal neuroendocrine tumors and their metastasis. A panel of Islet-1, CDX2 and TTF1 may be useful in differentiation well-differentiated endocrine carcinomas of unknown origin.

Composition: Anti-human Islet 1 rabbit monoclonal antibody purified from culture supernatant, filtered, sterilized and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name:PD-1 Antibody clone NAT105

Description and aplications: Programmed death-1 (PD-1) is a member of the CD28 family of receptors that includes CD28, cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4), inducible costimulator (ICOS), and B- and T-lymphocyte attenuator. These receptors play a role in the cellular immune response. For example, CD28 serves as a costimulatory receptor that enhances T-cell activation, whereas CTLA-4 serves as an inhibitor of T-cell activation. PD-1 also has an inhibitory function on T cells and B cells, and is important in peripheral tolerance. There are at least 2 ligands for PD-1, PD-L1, and PD-L2, which are expressed on a range of cells.
CD28 is constitutively expressed on most or all CD4+ T cells and approximately 50% of CD8+ T cells, whereas CTLA-4 is not expressed on resting T cells. PD-1 is also expressed on activated T cells, B cells, and myeloid cells. Iwai and coworkers studied the microanatomic distribution of PD-1 in human tonsil and found that PD-1 is expressed on most T cells and a small subset of B cells in the light zone of germinal centers, but not elsewhere in the tonsil. On that basis, it was postulated that PD-1 may play a role in the process of clonal selection of centrocytes, which occurs in this subanatomic site in germinal centers.

Composition: anti-human PD-1 mouse monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name: PD-L1 Monoclonal Antibody clone CAL10

Description and applications:Programmed death ligand 1 (PD-L1, also known as CD274) inhibits tumor-reactive T cells via binding to the programmed death-1 (PD-1) receptor, rendering tumor cells resistant to CD8+ T cell-mediated lysis. Studies have shown that the inhibitory receptor PD-1 is expressed on tumor-infiltrating lymphocytes (TIL) while PD-L1 is expressed on tumor cells. Assessment of PD-L1 expression in combination with CD8+ TIL density may be a useful predictive metric in multiple cancers, including stage III NSCLC, hormone receptor negative breast cancer and sentinel lymph node melanoma. Clinical trials utilizing humanized chimeric antibodies that block inhibitory checkpoints, such as anti-PD-1 and anti-PD-L1, have demonstrated delayed tumor growth and increased survival. While identification of PD-L1 overexpression by IHC is not yet standardized, it has become increasingly  important to identify these tumors, as a directed therapy may improve clinical outcomes in these patients. In cutaneous melanoma, the targeting of PD1/PD-L1 has provided meaningful clinical benefit for patients in just the past 5-10 years. The use of IHC for protein identification, along with novel therapies, such as checkpoint inhibitors and vaccines, are generating new options for the treatment of cancer patients. The PD-L1 [CAL10] clone does not cross react with PDL2.

Composition: Anti-human PD-L1 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use: Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Immunogen: Peptide corresponding to the region within human PD-L1.

Name: PDX1 Monoclonal Antibody clone EP139

Description and applications: The homeobox 1 duodenal protein (PDX1) is a transcription factor that is required for the embryonic development of the pancreas and the maturation of the β-cells of the islets of Langerhans. Moreover, PDX1 activates somatostatin, glucokinase, islet amyloid polypeptide, and glucose transporter type 2 gene transcription. The PDX1 protein is encoded by the PDX1 gene, located in the chromosomal region 13q12.2. Clinically, mutations in the PDX1 gene have been shown to cause pancreatic agenesis and hereditary maturity onset diabetes mellitus of the young (MODY); likewise, the PDX-1 factor plays a major role in the pathogenesis of non-insulindependent (type II) diabetes mellitus. The PDX1 protein is initially expressed in the intestinal region of the embryo and then in the primitive pancreatic epithelium, where it allows its proliferation, branching, and differentiation. In the adult, this transcription factor is selectively expressed in endocrine cells, such as pancreatic beta cells, duodenum’s Brunner’s gland cells, and endocrine cells of the stomach’s pyloric region. Within the pancreas, PDX1 can also be observed in a subset of centroacinar and pancreatic duct exocrine cells, as well as in the beta cells of the islets of Langerhans. Increased expression of PDX1 has been reported in pancreatic (both exocrine and neuroendocrine), colon, and prostate tumours, suggesting that PDX1 may act as a biomarker in patients with these malignant tumours. However, further studies are needed to prove their specificity.

Composition: Anti-human PDX1 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use: Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Name: Anti-AMACR/p504s+Anti-p63 human cocktail (PIN cocktail) clone 13H4+4A4

Description and aplications: The main use of the combination of both antibodies in a single reagent is simultaneously immunostain prostate glands in order to detect whether or not neoplastic. In the case of prostate adenocarcinoma, neoplastic glands must present cytoplasmic staining produced by expression of p504s and absence of nuclear staining as these glands lack basal cells and thus are negative for p63. Normal or hyperplastic glands must present nuclear staining in the basal cell layer. The Due to the different pattern of staining of the antibodies included in the cocktail, the detection could be realised with a polyvalent HRP detection systems. Nevertheless, as the antibodies are developed in two different host, a dual detection system can be used.

Composition: anti-human AMACR/p50s rabbit monoclonal antibody + anti-human p63 mouse monoclonal antibody prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: Human AMACR polypeptide + aminoacids 1-250 of the N-terminal portion of the human p63 protein

Name: PMS2 Monoclonal Antibody clone EP51

Description and aplications: PMS2, a mismatch repair endonuclease, is a member of a family of genes involved in DNA mismatch repair. Carriers of the mismatch repair gene mutations have a high lifetime risk of developing Hereditary Non-Polyposis Colon Cancer (HNPCC) and several other cancers including endometrial cancer due to microsatellite instability (MSI) caused by accumulation of DNA replication errors in proliferating cells. Along with MLH1, MSH2 and MSH6, PMS2 antibody is helpful in diagnosis of MSI. An IHC study conducted by Mayo clinic on 535 cases with MSI-high, 90% of the tumors showed loss of MLH1, MSH2 and/or MSH6 expression, while 70% of the remaining cases showed isolated loss of PMS2 expression. The loss of PMS2 was associated with young age of diagnosis and right-sided location but not with a striking family history of cancer. Endometrial carcinomas are the most common noncolorectal cancers occur in HNPCC. The most common IHC abnormality in endometrial carcinomas with MSI was concurrent loss of MLH1/PMS2. Adding of PMS2 and MSH6 to MLH1 and MSH2 antibodies increased sensitivity for diagnosis of MSI. Tumors with low-level MSI show unfavourable pathological characteristics compared to tumours with no and tumours with highlevel MSI.

Composition: anti-human PMS2 rabbit monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Immunogen: A synthetic peptide corresponding to residues in human PMS2 protein

Name: PNL2 Monoclonal Antibody clone PNL2

Description and applications: PNL2, initially developed as a human somatostatin receptor marker, is a novel monoclonal antibody directed against an antigen (not well affiliated with melanocytes) that is chemically resistant to fixation and allows immunostaining after melanin bleaching and treatment with decalcifying agents. On a wide range of normal and neoplastic human tissues and compared to other similar markers such as HMB45, Melan A, MiTF, CD63, MAGE1, MAGE3, or tyrosinase, this antibody has revealed high specificity for melanocytes and for various benign and malignant melanocytic lesions derived from them. When the anti-PNL2 antibody is used on normal tissues, it gives a strong cytoplasmic staining of skin and oral mucosae melanocytes, as well as of granulocytes and osteoclast-like multinucleated giant cells when used at high concentration. In benign melanocytic lesions, PNL2 labels intraepidermal nevi, whereas intradermal nevi and the dermal component of compound nevi are basically negative although scattered nevus cells in the papillary dermis are usually positive. In primary melanomas, irrespective of their histologic type, PNL2 usually labels more than 70% of the neoplastic cells. In this context and within a broader panel of antibodies, PNL2 may contribute to the differential diagnosis between atypical nevus lesions and melanomas, although this antibody does not label desmoplastic melanomas. Moreover, the vast majority of metastatic melanomas are positive against PNL2 and, although the proportion of labelled cells is occasionally lower than in the primary tumour, it is always greater than that obtained with the commonly used markers for these tumours (HMB45 and Melan A). Like Melan A and HMB-45, PNL2 also stains most of the clear cell sarcoma cells, and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Other non-melanocytic lesions positive for this antibody include PEComas and melanotic schwannoma. In isolated cases of chronic myeloid leukaemia, the PNL2 antibody stains neutrophils and myelocites, while blast cells are negative.

Composition: Anti-human PNL2 mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name: L1CAM Antibody clone BSR3

Description and applications:L1CAM (L1 cell adhesion molecule protein) is a cell adhesion molecule with an important role in the development of the nervous system. The L1, neural cell adhesion molecule (L1CAM) plays an important role in axon growth, fasciculation, neural migration and in mediating neuronal differentiation. L1 protein is expressed to tissues arising from neuroectoderm. L1CAM plays also an important role in the malignancy of human tumors and according to several studies, L1CAM positive carcinomas have a bad prognosis. L1CAM is overexpressed in many human carcinomas but it is useful especially in endometrium carcinoma diagnostic.

Composition : Anti-human L1CAM rabbit monoclonal antibody purified from culture supernatant, filtered, sterilized and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Name: p21/Waf-1 (DCS-60.2)

Description and aplications: p21WAF1/Cip1/Sdi1/Pic1 is a tumor suppressor protein. Expression of p21WAF1 is induced by wild type, but not mutant, p53 suppressor protein. The p21WAF1 protein binds to cyclin/CDK complexes and inhibits their kinase activity thereby stopping cell cycle progression. It also binds to PCNA (proliferating cell nuclear antigen) and blocks DNA replication but not the DNA repair process.

Composition: anti-human p21 mouse monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Visualization: Nuclear